Company's stock surged over 100% after positive 96-week results from its phase 2b SYMMETRY study using EFX to treat F4 compensated cirrhosis due to MASH patients. The company achieved a significant reversal of cirrhosis, with 39% of patients showing improvement compared to 15% on placebo, highlighting EFX's efficacy. Upcoming catalysts include phase 3 SYNCHRONY studies targeting F1-F3 and F2-F3 MASH patients, with data expected in the first half of 2026 and 2027, respectively.
Equifax has agreed to a settlement and consent order that will resolve Consumer Financial Protection Bureau (CFPB) allegations that the consumer reporting agency failed to take steps to ensure the accuracy of its credit reports.
The U.S. Consumer Financial Protection Bureau announced on Friday it had fined credit reporting bureau Equifax $15 million for failing to sufficiently investigate consumer disputes of its credit reports.
Equifax's transition to its own cloud and EFX.AI capabilities will drive revenue growth, margin expansion, and increased free cash flow, enhancing profitability. Lower CapEx and higher margins will boost earnings, with EPS expected to grow significantly, supporting a one-year price target of $306.75 and a Strong Buy rating. The new cloud platform will improve productivity, benefiting shareholders with increased returns.
EFX stock is gaining from the services provided to its huge client base and product portfolio, which keeps the company ahead of its peers.
Equifax and Mastercard have partnered to provide fraud management tools to businesses in Latin America, excluding Brazil. This collaboration will make these tools available to Mastercard business customers in Latin America — including financial institutions, payment service providers, acquiring banks and merchants — through Equifax's Kount Payment Fraud solution, the companies said in a Thursday (Dec. 5) press release.
Investors need to pay close attention to Equifax (EFX) stock based on the movements in the options market lately.
EFX is leveraging acquisitions to expand its presence around the globe, and assist its customers to cater to their employment and hiring needs.
I maintain a buy rating for Equifax due to accelerating growth in mortgage-related revenue and an improving free cash flow profile. EFX's 3Q24 results showed strong revenue growth, driven by a significant increase in mortgage solutions and expanding international revenue. Challenges in non-mortgage revenue persist, but I expect these to ease as macroeconomic conditions improve, supporting future growth.
Examine Equifax's (EFX) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Equifax Inc. (NYSE:EFX ) Q3 2024 Earnings Conference Call October 17, 2024 8:30 AM ET Company Participants Trevor Burns - Senior Vice President, Head of Corporate Investor Relations Mark Begor - Chief Executive Officer John Gamble - Chief Financial Officer Conference Call Participants Manav Patnaik - Barclays Kelsey Zhu - Autonomous Research Andrew Nicholas - William Blair Surinder Thind - Jefferies Kyle Peterson - Needham & Company Scott Wurtzel - Wolfe Research Kevin McVeigh - UBS Jason Haas - Wells Fargo Jeff Meuler - Baird Owen Lau - Oppenheimer Craig Huber - Huber Research Partners Toni Kaplan - Morgan Stanley Ashish Sabadra - RBC Capital Markets George Tong - Goldman Sachs Andrew Stein - FT Partners Operator Greetings, and welcome to the Equifax Inc. Third Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode.
EFX's Workforce Solutions and USIS segments exceed expectations, while the International division misses the same in the third quarter of 2024.